28 days of treatment with AC2993 (synthetic exendin-4) improved glycemic control in patients with Type 2 diabetes concomitantly treated with metformin (met) and/or sulfonylurea (sfu)

被引：0
|
作者：
Fineman, M [1 ]
Bicsak, T [1 ]
Shen, L [1 ]
Taylor, K [1 ]
Gaines, E [1 ]
Varns, A [1 ]
Kim, D [1 ]
Baron, A [1 ]
机构：
[1] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
DIABETOLOGIA | 2002年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
124
引用
收藏
页码：A44 / A44
页数：1
相关论文
共 41 条
  • [1] AC2993 (Synthetic exendin-4) added to existing metformin (Met) and/or sulfonylurea (SFU) treatment improved glycemic control in patients with type 2 diabetes (DM2) during 28 days of treatment
    Fineman, MS
    Bicsak, T
    Shen, L
    Taylor, K
    Gaines, E
    Varns, A
    Kim, D
    Baron, A
    DIABETES, 2002, 51 : A85 - A85
  • [2] Continuous subcutaneous infusion of AC2993 (Synthetic exendin-4) provides sustained, day-long glycemic control to patients with type 2 diabetes
    Taylor, K
    Kim, D
    Bicsak, T
    Heintz, S
    Varns, A
    Aisporna, M
    Fineman, MS
    Baron, A
    DIABETES, 2002, 51 : A85 - A85
  • [3] Continuous subcutaneous infusion of AC2993 (synthetic exendin-4) provides sustained day-long glycemic control in patients with Type 2 diabetes
    Taylor, K
    Kim, D
    Bicsak, T
    Heintz, S
    Varns, A
    Aisporna, M
    Fineman, M
    Baron, A
    DIABETOLOGIA, 2002, 45 : A43 - A44
  • [4] Effects of exenatide (exendin-4) on glycemic control and weight in patients with Type 2 diabetes treated with metformin and a sulfonylurea
    Kendall, DM
    Riddle, MC
    Zhuang, D
    Kim, DD
    Fineman, MS
    Baron, AD
    DIABETOLOGIA, 2004, 47 : A279 - A280
  • [5] Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes
    Fineman, MS
    Bicsak, TA
    Shen, LZ
    Taylor, K
    Gaines, E
    Varns, A
    Kim, D
    Baron, AD
    DIABETES CARE, 2003, 26 (08) : 2370 - 2377
  • [6] Effects of five-day dosing of synthetic exendin-4 (AC2993) in people with type 2 diabetes
    Buse, J
    Fineman, M
    Gottlieb, A
    Gaines, E
    Kolterman, O
    DIABETES, 2000, 49 : A100 - +
  • [7] AC2993 (synthetic exendin-4) lowered postprandial plasma glucose concentrations in people with type 2 diabetes.
    Kolterman, O
    Fineman, M
    Gottlieb, A
    Petrella, E
    Pricket, K
    Young, A
    DIABETOLOGIA, 1999, 42 : A41 - A41
  • [8] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    Kendall, DM
    Riddle, MC
    Rosenstock, J
    Zhuang, DL
    Kim, DD
    Fineman, MS
    Baron, AD
    DIABETES CARE, 2005, 28 (05) : 1083 - 1091
  • [9] AC2993 (synthetic exendin-4) lowered fasting glucose concentrations through suppression of glucagon and dose dependent insulinotropism in patients with Type 2 diabetes
    Kim, D
    Taylor, K
    Bicsak, T
    Wang, Y
    Aisporna, M
    Heintz, S
    Fineman, M
    Baron, A
    DIABETOLOGIA, 2002, 45 : A44 - A44
  • [10] Dose-response for postprandial glucose-lowering effect of synthetic exendin-4 (AC2993) in subjects with type 2 diabetes
    Fineman, M
    Young, A
    Gaines, E
    Prickett, K
    DIABETES, 2000, 49 : A106 - A106
12345